ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0218

A Web-based Education Program Improves Health Care Provider Knowledge for the Care of Cancer Patients Receiving Immunotherapy Who Develop Rheumatic Immune-related Complications, and Those with Pre-existing Rheumatic Disease: An Initiative of CanRIO

Janet Roberts1, Keith Lau2, Daniel Ennis3, Marie Hudson4, Shahin Jamal3, Steven Katz2 and Carrie Ye2, 1Dalhousie University, Halifax, NS, Canada, 2University of Alberta, Edmonton, AB, Canada, 3University of British Columbia, Vancouver, BC, Canada, 4McGill University, Montréal, QC, Canada

Meeting: ACR Convergence 2022

Keywords: Education, immunology

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Professional Education Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Immunotherapy has revolutionized the treatment of many advanced stage malignancies. These agents harness the immune system to fight cancer. However, use of these agents leads to many off-target effects known as immune-related adverse events (irAE). The management of patients with rheumatic immune-related adverse events (Rh-irAE) as well as cancer patients with pre-existing autoimmune rheumatic disease (PAD) is challenging as treatment of their rheumatic disease can lead to attenuation of the cancer therapy. This is a rapidly evolving area of medicine and previous studies have shown that many rheumatologists lack experience, knowledge and confidence in the management of these patients.1,2 Our goal was to improve the knowledge of health care providers on two specific patient populations: (i) cancer patients who develop de-novo Rh-irAE and (ii) patients with PAD being treated with immunotherapy. Our goal was to achieve knowledge transfer through the development of an educational platform that facilitates cross-discipline and transregional collaboration and to support health care providers caring for these patients to ensure educational resources are both available and easily accessible.

Methods: We developed multiple tools to facilitate knowledge acquisition and transfer including a) five case-based learning modules (with pre- and post-module tests), b) interactive bi-monthly video conferences, and c) development of a website to house educational resources. This website (www.canrio.ca) houses the learning modules, registration for video conferences, as well as other educational resources for health care providers. Google Analytics is embedded within the www.canrio.ca website and was used to track website traffic since the website’s inception in February 2021. Immediate knowledge acquisition was assessed following completion of the learning modules by comparing mean pre- and post-module test scores. Long-term knowledge retention was assessed by test scores 3 months following completion of the learning module.

Results: Between February 2021 and May 2022, 893 users from 36 different countries accessed the www.canrio.ca website. The top three countries from which users accessed the site were Canada (59%), United States of America (17%) and China (15%). The case-based learning modules resulted in immediate knowledge acquisition with a statistically significant increase from pre- to post-test scores for all five modules (Table 1). Long-term knowledge retention remains unclear as only 14% of eligible users completed the 3-month follow-up test.

Conclusion: CanRIO.ca, a web-based, open access educational platform is an effective tool for delivering content and promoting knowledge acquisition on rheumatic complications of cancer immunotherapy to healthcare providers around the world.

Supporting image 1

Ir=immune-related; IA = inflammatory arthritis; PAD = pre-existing autoimmune rheumatic disease; SLR=sarcoid-like reaction


Disclosures: J. Roberts, Bristol-Myers Squibb(BMS), Pfizer, AbbVie/Abbott, Novartis; K. Lau, None; D. Ennis, None; M. Hudson, Bristol-Myers Squibb(BMS), Boehringer-Ingelheim, Mallinckrodt; S. Jamal, AbbVie/Abbott, Amgen, Bristol-Myers Squibb(BMS), Eli Lilly, Merck/MSD, Pfizer, Janssen, Roche, UCB; S. Katz, None; C. Ye, None.

To cite this abstract in AMA style:

Roberts J, Lau K, Ennis D, Hudson M, Jamal S, Katz S, Ye C. A Web-based Education Program Improves Health Care Provider Knowledge for the Care of Cancer Patients Receiving Immunotherapy Who Develop Rheumatic Immune-related Complications, and Those with Pre-existing Rheumatic Disease: An Initiative of CanRIO [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/a-web-based-education-program-improves-health-care-provider-knowledge-for-the-care-of-cancer-patients-receiving-immunotherapy-who-develop-rheumatic-immune-related-complications-and-those-with-pre-exi/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-web-based-education-program-improves-health-care-provider-knowledge-for-the-care-of-cancer-patients-receiving-immunotherapy-who-develop-rheumatic-immune-related-complications-and-those-with-pre-exi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology